ReviewClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026
VPS9D1-AS1: a critical oncogenic long non-coding RNA in human malignancies.
Review in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Integrated psychosocial, sleep, and immunonutritional intervention improves psychological adaptation, sleep disturbance, and inflammatory activation in rectal cancer: a randomized controlled trial.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Trial
- Role of long non-coding RNA HCG11 in human cancers: From molecular mechanisms to clinical applications (Review).Oncology letters · 2026Review
- Perioperative physiological complexity trajectories and their association with molecular residual disease and long-term outcomes after curative colorectal cancer surgery: a prospective cohort study.Surgical endoscopy · 2026Article
- A multidomain sleep-brain vulnerability index predicts delirium and long-term cognitive decline in hospitalized older adults.European geriatric medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Long non-coding RNAs (lncRNAs) exceeding 200 nucleotides participate in the physiological and pathological pathways of various cancers. VPS9D1 antisense RNA 1 (VPS9D1-AS1), situated in the q24.3 region of human chromosome 16 and known as c-Myc upregulation factor (MYU), is upregulated in multiple tumor types. This lncRNA mainly plays a cancer-promotional role by modulating target genes, adsorbing microRNAs (miRNAs), and involving in the regulation of numerous pivotal signaling pathways, such as Wnt/β-catenin, TGF-β/ISG, and PI3K/AKT. Collectively, these molecular mechanisms promote malignant phenotypes, including proliferation, invasion, migration, and epithelial-mesenchymal transition (EMT) of cancer cells. Clinical studies have indicated that high expression levels of VPS9D1-AS1 are closely associated with tumor volume enlargement, progression in clinical staging, increased risk of metastasis, and poor prognosis. This review systematically elucidates the role, molecular mechanisms, and clinical application value of VPS9D1-AS1 in malignant tumors, emphasizing its potential as a diagnostic biomarker and therapeutic target.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.